Name of the Issue: Star Health and Allied Insurance Company Limited

1	**Type of Issue**	Initial Public Offer
2	**Issue Size (Rs. Cr)** (1)	6,400.4

Source:
(1) Prospectus dated December 07, 2021

3 Grade of issue along with name of the rating agency

Name	NA
Grade	NA

4 Subscription Level (Number of times)(1) 0.95x

Source: Basis of allotment dated December 09, 2021

Note: (1) Excluding Anchor Investor Portion and after removing multiple and duplicate bids, bids not banked / blocked, bids rejected under application banked but bid not registered and technical rejections case.

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) Allotment in the Issue(1)	37.18%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2021)	37.35%
(iii) at the end of 1st FY (March 31, 2022)	37.08%
(iv) at the end of 2nd FY (March 31, 2023)	36.68%
(v) at the end of 3rd FY (March 31, 2024)	37.72%
(v) at the end of 4th FY (March 31, 2025)(2)	N.A.

Source: Regulatory Filings with the stock exchange

Note: (1) Basis of allotment
(2) Will be updated in the due course

6 Financials of the Issuer

(Rs. Crore)

Parameters	1st FY(March 31, 2022)	2nd FY(March 31, 2023)	3rd FY(March 31, 2024)	4th FY(March 31, 2025)[1]
Revenue from operations (Gross Written Premium)	11,463.5	12,952.5	15,254.5	N.A.
Net Profit	(1,040.7)	618.6	845.01	N.A.
Paid up Equity Share Capital	575.5	581.7	585.28	N.A.
Reserves excluding revaluation reserves	4,028.5	4,852.3	5,756	N.A.

Note: (1) Will be updated in due course

7 Trading Status

Company's Equity Shares are listed on both the BSE Limited and the NSE.The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024)[1]	Frequently Traded

Note: (1) Trading status has not been disclosed since the relevant financial year has not been completed

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	V. Jagananathan	Appointed
(ii) at the end of 2nd FY (March 31, 2023)	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2024)	Anand Roy	Appointed
	Berjis Minoo Desai	Resigned
	Dr. S Prakash	Resigned
	D R Kaarthikeyan	Retirement
	V. Jagananathan	Resigned
(iii) at the end of 3rd FY (March 31, 2025)[1]	Rajeev Kher	Appointed

Note: (1) Will be further updated in due course

9 Status of implementation of project/ commencement of commercial production

(i) As disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document (Rs Cr)[(1)]	2,000
(ii) Actual utilization (Rs Cr)	2,000
(iii) Reasons for deviation, if any	Not applicable

Note:(1) Gross proceeds of the issue.

Utilization of proceeds as per prospectus is to augment company's capital base & maintain solvency levels. The issue proceeds are used for the intended purpose

11 Comments of monitoring agency, if applicable[(1)]

(a) Comments on use of funds	Not applicable
(b) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(c) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

(1) As per Prospectus dated December 07, 2021, the company is not required to appoint a monitoring agency. However, the company has submitted a dislcosure to BSE stating no deviation or variation in the use of proceeds

12 Pricing Data

Issue Price (Rs.)	900
Designated Stock Exchange:	BSE
Listing Date:	10-Dec-21

Price parameters	At close of listing day- December 10, 2021	Close of 30th calendar day from listing day (January 7, 2022)	Close of 90th calendar day from listing day (March 09, 2022)	At the end of FY 2022			At the end of FY 2023			At the end of FY 2024			At the end of FY 2025		
				Closing price	High	Low	Closing price	High	Low	Closing price	High	Low	Closing price	High	Low
Market Price (BSE)	906.9	766.4	633.2	710.7	940.0	603.0	518.5	780.0	451.1	543.1	675.0	477.0	N.A.	N.A.	N.A.
Sensex (BSE Index)	58,786.7	59,744.7	54,647.3	58,568.5	62,245.4	47,204.5	58,991.5	63,583.1	50,921.2	73,651.4	74,245.2	58,273.9	N.A.	N.A.	N.A.

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

13 **Basis for Issue Price**

Accounting ratio	Name of Company	As disclosed in the offer document, at the end of FY 2021	At the end of 1st FY (FY 2022)	At the end of 2nd FY (FY 2023)	At the end of 3rd FY (FY 2024)	At the end of 3rd FY (FY 2025)(1)
EPS (Basic)(Rs.)	**Issuer :**	-16.5	-18.7	10.7	14.5	N.A.
	Peer Group & Industry	21.2	13.5	20.8	22.9	N.A.
	ICICI Lombard General Insurance Co. Ltd.	32.4	25.9	35.2	39.0	N.A.
	New India Assurance Company Ltd.	10.0	1.2	6.4	6.85	N.A.
P/E (Basic)	**Issuer:**	N.M.	N.M.	48.5	37.5	N.A.
	Peer Group & Industry Average	31.0	74.5	22.8	38.2	N.A.
	ICICI Lombard General Insurance Co. Ltd.	46.7	52.0	30.4	43.2	N.A.
	New India Assurance Company Ltd.	15.3	96.9	15.2	33.2	N.A.
RoNW (%)	**Issuer:**	-23.7%	-23.0%	0.1%	13.3%	N.A.
	Peer Group & Industry	14.3%	7.4%	11.0%	10.5%	N.A.
	ICICI Lombard General Insurance Co. Ltd.	19.8%	14.0%	16.6%	16.0%	N.A.
	New India Assurance Company Ltd.	8.8%	0.9%	5.3%	5.0%	N.A.
NAV per share	**Issuer:**	63.6	78.7	0.0	108.3	N.A.
	Peer Group & Industry	137.9	148.3	166.2	187.7	N.A.
	ICICI Lombard General Insurance Co. Ltd.	163.6	185.6	211.6	242.7	N.A.
	New India Assurance Company Ltd.	112.2	111.0	120.9	132.6	N.A.

Note:

N.A. represents Not Available; N.M. represents Not Meaningful

(1) Will be updated in due course

14 Any other material information

Particulars	Date	Remarks
Appointed Mr Amit Nagdev as Deputy Chief Risk Officer following the resignation of Mr Kapil Punwani, Chief Risk Officer	23-Nov-24	-
Appointed Ashwani Kumar Arora as Actuary of the Company	29-Oct-24	-
Assigned a rating of AA+and the subordinate debt of the Company has been assigned a rating of AA by India Ratings	02-Oct-24	-
Reported Q2FY25 results	29-Oct-24	-
Appointed Mr. Rajeev Kher as the Independent Director of the Company	11-Jun-24	-
Redisgnation of Dr. Sriharsha A Achar, Chief Human Resource Officer as Advisor - HR & Non - KMP, who initally retired early	07-May-24	-
Board have aprpoved the reappointment of M/s Brahmayya & Co and M/s V Sankar Aiyar & Co as Joint Staturory Auditors for a second consecutive term of fiver years from 19th AGM till 24th AGM	30-Apr-24	-
Appointed M. Jayaraman as the Appointed Actuary and Key Managerial Personnel of the Company	30-Apr-24	-
Resignation of Mr. Berjis Minoo Desai as Independent Director of the Company	24-Apr-24	-
Has been assigned a rating of AA+ by Care Rating	05-Apr-24	-
Resignation of Mr. Chandrasekhar Dwivedi, Appointed Actuary and Key Managerial Personnel	09-Feb-24	-
Mr. N. Chittibabu, Chief Innovation Officer and Key Managerial Personnel of Star Health & Allied Insurance has resigned from his position, which will be effective from the close of business hours on February 18,2024	19-Jan-24	-
Dr. S. Prakash, Strategic Management Executive of Star Health & Allied Insurance has resigned from his position, which will be effective from the close of business hours on November 27,2023	30-Nov-23	-
Appointment of KMP: Mr. Chittibabu N (Chief Innovation Officer); Mr. Mukesh Sharma (Chief Digital Transformation Officer); Mr. Biju Menon (Chief Buinsess Officer); Mr. Vishwajeet Mohnot (Chief Compliance Officer - w.e.f. 15th August, 2023)	28-Jul-23	-
Re-classification of certain officials of the Company as Non KMP and Non- Senior Management: Dr. Harikrishnan K (Senior Executive Director, Marketing); Mr. Sundaresan S (Senior Executive Director); Mr. Kumar K C (Senior Executive Director, Human Resources); Mr. Jayaprakash V (Chief Compliance Officer - w.e.f. 15th August, 2023	28-Jul-23	-
Mr. Anand Roy appointed as the MD & CEO effective from May 5, 2023	28-Apr-23	
Mr. Venkatasamy. Jagannathan, CEO of Star Health & Allied Insurance has relinquished his position and would continue as the Non Executive Director and Non-Executive Chairman of the Board, which will be effective from the close of business hours on May 4,2023	28-Apr-23	-
Death of the promoter - Mr. Rakesh Jhunjhunwala	30-Aug-22	-

Note: For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the “Circular”) for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as “www.capitalmarkets.com“ and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of September 26, 2024. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.